Nisa Investment Advisors LLC Reduces Stock Holdings in Medtronic PLC $MDT

Nisa Investment Advisors LLC reduced its position in shares of Medtronic PLC (NYSE:MDT) by 46.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 222,632 shares of the medical technology company’s stock after selling 191,790 shares during the period. Nisa Investment Advisors LLC’s holdings in Medtronic were worth $21,362,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Norges Bank purchased a new stake in shares of Medtronic during the 2nd quarter valued at approximately $1,432,698,000. Vanguard Group Inc. increased its stake in Medtronic by 1.5% during the second quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock worth $11,062,693,000 after acquiring an additional 1,895,165 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in Medtronic by 332.0% in the second quarter. Arrowstreet Capital Limited Partnership now owns 1,494,782 shares of the medical technology company’s stock valued at $130,300,000 after purchasing an additional 1,148,803 shares during the period. Perkins Coie Trust Co raised its position in Medtronic by 2,952.2% in the second quarter. Perkins Coie Trust Co now owns 1,155,425 shares of the medical technology company’s stock valued at $100,718,000 after purchasing an additional 1,117,570 shares during the period. Finally, Laurel Wealth Advisors LLC lifted its stake in shares of Medtronic by 8,779.8% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 1,069,664 shares of the medical technology company’s stock valued at $93,243,000 after purchasing an additional 1,057,618 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Cowen reissued a “buy” rating on shares of Medtronic in a research report on Friday, November 14th. Morgan Stanley lifted their price target on shares of Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. Stifel Nicolaus boosted their price target on shares of Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. JPMorgan Chase & Co. increased their price objective on shares of Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a research report on Thursday, November 13th. Finally, Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eleven have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $110.28.

Medtronic Stock Performance

Shares of MDT stock opened at $97.54 on Friday. The firm has a 50 day moving average of $98.31 and a two-hundred day moving average of $94.45. The stock has a market capitalization of $125.04 billion, a PE ratio of 26.29, a P/E/G ratio of 2.60 and a beta of 0.71. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. The business had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company’s revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 16th. Stockholders of record on Friday, December 26th will be paid a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is presently 76.55%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).